Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function

Overview

Journal J Investig Med High Impact Case Rep

Specialty General Medicine

Date 2017 Feb 17

PMID 28203577

Citations 8

Authors

S Scott Sutton

Mark Jumper

Sean Cook

Babatunde Edun

Michael D Wyatt

Affiliations

Soon will be listed here.

Abstract

Drug-induced neurotoxicity is a rare adverse reaction associated with ertapenem. Encephalopathy is a type of neurotoxicity that is defined as a diffuse disease of the brain that alters brain function or structure. We report a patient with renal function who developed ertapenem-induced encephalopathy manifesting as altered mental status, hallucinations, and dystonic symptoms. The patient's symptoms improved dramatically following ertapenem discontinuation, consistent with case reports describing ertapenem neurotoxicity in renal dysfunction. Since clinical evidence strongly suggested ertapenem causality, we utilized the Naranjo Scale to estimate the probability of an adverse drug reaction to ertapenem. Our patient received a Naranjo Scale score of 7, suggesting a probable adverse drug reaction, with a reasonable temporal sequence to support our conclusion.

Citing Articles

Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury.

Farooq S, Acosta A BMJ Case Rep. 2024; 17(1).

PMID: 38171638 PMC: 10773332. DOI: 10.1136/bcr-2023-256876.

A Rare Case of Late-Onset Ertapenem-Induced Encephalopathy.

Teague A, Gupta S, Paul V Cureus. 2023; 15(8):e43713.

PMID: 37724203 PMC: 10505488. DOI: 10.7759/cureus.43713.

Abnormal inpatient EEG predicts seizure occurrence independently of renal function.

Matta C, Hamze R, Abi-Nahed R, Azar H, Abou Khaled K Epilepsy Behav Rep. 2023; 23:100615.

PMID: 37635921 PMC: 10448409. DOI: 10.1016/j.ebr.2023.100615.

Peripheral Neuropathy Secondary to Ertapenem Administration for Treatment of Infectious Endocarditis.

Buckman P, Scatton C, Cappola J Cureus. 2023; 15(4):e37253.

PMID: 37162774 PMC: 10164356. DOI: 10.7759/cureus.37253.

Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.

Fernandez-Rubio B, Luque-Marquez R, Gil-Navarro M Daru. 2022; 30(1):159-163.

PMID: 35023080 PMC: 9114266. DOI: 10.1007/s40199-021-00425-5.

References

Oo Y, Packham D, Yau W, Munckhof W . Ertapenem-associated psychosis and encephalopathy. Intern Med J. 2014; 44(8):817-9. DOI: 10.1111/imj.12504. View

Norrby S . Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000; 45(1):5-7. DOI: 10.1093/jac/45.1.5. View

Miller A, Ball A, Bookstaver P, Dornblaser E, Bennett C . Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011; 31(4):408-23. DOI: 10.1592/phco.31.4.408. View

Calandra G, Lydick E, Carrigan J, WEISS L, Guess H . Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med. 1988; 84(5):911-8. DOI: 10.1016/0002-9343(88)90071-x. View

Wen M, Sung C, Chau T, Lin S . Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Clin Nephrol. 2012; 80(6):474-8. DOI: 10.5414/CN107247. View

Schliamser S, Cars O, Norrby S . Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991; 27(4):405-25. DOI: 10.1093/jac/27.4.405. View

Sunagawa M, Matsumura H, Sumita Y, Nouda H . Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo). 1995; 48(5):408-16. DOI: 10.7164/antibiotics.48.408. View

Duquaine S, Kitchell E, Tate T, Tannen R, Wickremasinghe I . Central nervous system toxicity associated with ertapenem use. Ann Pharmacother. 2010; 45(1):e6. DOI: 10.1345/aph.1P528. View

Hikida M, Masukawa Y, Nishiki K, Inomata N . Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother. 1993; 37(2):199-202. PMC: 187638. DOI: 10.1128/AAC.37.2.199. View

10.

Lee K, Ueng Y, Wu C, Chou Y, Ng Y, Yang W . The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. J Clin Pharm Ther. 2014; 40(2):240-4. DOI: 10.1111/jcpt.12239. View

11.

Wallace K . Antibiotic-induced convulsions. Crit Care Clin. 1997; 13(4):741-62. DOI: 10.1016/s0749-0704(05)70367-5. View

12.

Kong V, Beckert L, Awunor-Renner C . A case of beta lactam-induced visual hallucination. N Z Med J. 2009; 122(1298):76-7. View

13.

Chow K, Hui A, Szeto C . Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis. 2005; 24(10):649-53. DOI: 10.1007/s10096-005-0021-y. View

14.

Chow K, Szeto C, Hui A, Kam-Tao Li P . Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrob Agents. 2004; 23(3):213-7. DOI: 10.1016/j.ijantimicag.2003.11.004. View

15.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

16.

Cannon J, Lee T, Clark N, Setlak P, Grim S . The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014; 69(8):2043-55. DOI: 10.1093/jac/dku111. View

17.

Norrby S . Neurotoxicity of carbapenem antibacterials. Drug Saf. 1996; 15(2):87-90. DOI: 10.2165/00002018-199615020-00001. View

18.

Shea Y, Mok M, Cheng K, Hon F, Chu L . Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Int J Clin Pharm. 2013; 35(4):535-7. DOI: 10.1007/s11096-013-9812-x. View

19.

Norrby S . Carbapenems in serious infections: a risk-benefit assessment. Drug Saf. 2000; 22(3):191-4. DOI: 10.2165/00002018-200022030-00003. View

20.

Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K . Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006; 222(1-2):114-24. DOI: 10.1016/j.tox.2006.02.004. View